![How is CBtru®, a novel drug product intermediate, pioneering patient-friendly CBD-based therapies? An expert view](/content/dsm/pharma/en/news/dsm-pharma-blog/ask-the-expert-cbtru.thumb.390.390.png/1719408976536.jpg)
We know how important it is to stay up-to-date with the latest news, regulatory updates and results from key clinical trials. This section will keep you at the forefront of recent advances in the pharmaceutical industry, including science-backed therapeutic benefits of vitamin active pharmaceutical ingredients, events and dsm-firmenich’s latest business developments.
19 Oct 2023 4 min
13 Sep 2023 4 min
27 Jul 2023 6 min
04 Aug 2022 4 min
dsm-firmenich has announced the launch of CBtru® – an advanced formulated cannabidiol (CBD) drug product intermediate designed for oral solid delivery formats.
dsm-firmenich is proud to announce its new strategic collaboration with Oz Medicann Group (OMG), to explore the therapeutic potential of cannabidiol (CBD) bases orally dispersible tablets addressing insomnia.
dsm-firmenich is proud to announce its strategic partnership with Zerion Pharma, to unlock a new era in cannabinoid innovation.
Stay up-to-date on the latest science, events and market trends